Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Three-drug combo promising against high-risk CLL

Publish date:: June 15, 2020

Key clinical point: A three-drug combination may improve response rates in high-risk CLL.

Major finding: The CR/CRi rate was 58.5%.

Study details: Prospective open-label phase 2 trial in 41 patients with CLL with del(17p) and/or TP53 mutations.

Disclosures: The trial was supported by Janssen-Cilag and Roche. Dr. Huber disclosed travel reimbursement from Novartis. Dr. Danilov disclosed consulting for AbbVie, Janssen, and Genentech.

Citation:

Huber H et al. EHA Congress. Abstract S157.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in CLL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Pigment traits, sun sensitivity associated with risk of non-Hodgkin lymphomas and chronic lymphocytic leukemia,

Ibrutinib associated with decreased circulating malignant cells and restored T-cell function in CLL patients,

Final ASCEND study data: Acalabrutinib beat standard of care for r/r CLL,

Meta-analysis: Acalabrutinib showed better PFS and OS than other frontline CLL therapies,